

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.

Primary IR Contact

Investor Relations

Phone: 617.679.5500

E-mail:

ir@iderapharma.com

Stock Information

IDRA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$1.76**

Change (%) **▼** 0.14 (7.37%)

Volume 1,164,968

52 Week Low \$1.30


Market Cap \$283,381,930

Rolling EPS -0.31

PE Ratio 0

Shares Outstanding 149,148,384

Data as of 06/27/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Headlines

Jun 22, 2017

Idera Announces FDA Orphan Drug Designation for

IMO-2125 for the Treatment of Melanoma

Events

There are currently no events scheduled.

Jun 05, 2017

Idera to Present at the Jefferies 2017 Healthcare

Conference

May 04, 2017

Idera Pharmaceuticals Reports First Quarter 2017 Financial

Results and Provides Corporate Update

SEC Filings

Filing Date	Form
06/09/17	4
06/09/17	4
06/09/17	4
06/09/17	4

Corporate Governance	
Sudhir Agrawal,	President of Research
D.Phil.	
Louis J. Arcudi	Senior Vice President of Operations,
III, MBA	Chief Financial Officer, Treasurer, and
	Secretary
Mark J. Casey	Senior Vice President, General Counsel
	and Secretary of the Board of
	Directors
Jill Conwell	Vice President, Human Resources
Dohout Doody, In	Wine Describent Investor Deletions and
Robert Doody Jr.	Vice President, Investor Relations and
	Corporate Communications
Clayton Fletcher	Senior Vice President, Business
	Development and Strategic Planning
Joanna Horobin,	Senior Vice President, Chief Medical
M.B., Ch.B.	Officer

Chief Executive Officer

Vincent Milano